News

Substitution Treatment of von Willebrand Disease with vWF and FVIII Concentrates

29. 11. 2022 Source: Von Willebrand Disease

Recently published recommendations from Poland regarding the diagnosis and treatment of von Willebrand disease (vWD) provide a comprehensive summary of the current approach to substitution therapy using concentrates containing von Willebrand factor (vWF) and coagulation factor VIII (FVIII), administered primarily during bleeding or surgical procedures.

medicína_lékaři_porada_meeting_konzilium

ITP from the Patients' Perspective: How It Affects Their Lives and Which Needs They Find Unmet?

In recent years, new therapeutic options for immune thrombocytopenia (ITP) have been introduced, which are effective for many patients and have significantly improved their quality of life. However,…

28. 11. 2022 Source: Immune Thrombocytopenia

Can we finally reliably distinguish between viral and bacterial pneumonia, or identify the specific cause? Promising results from a nanoparticle-based test

The etiology of pneumonia involves a wide range of pathogens, and distinguishing between bacterial and viral pneumonia is often not easy. In clinical practice, patients with viral pneumonia are…

28. 11. 2022 Source: proLékaře.cz

Benefits of Physical Activity for Individuals with Hemophilia –⁠ Recommendations of the MEMO Group

Regular physical activity can increase joint stability and function in individuals with hemophilia, reduce the risk of injury, improve quality of life, and have other positive effects. However,…

25. 11. 2022 Source: Hemophilia with Movement

Romiplostim Before Splenectomy in a Patient with ITP -⁠ Case Report

In the following case report from authors at a university hospital in Barcelona, the successful use of romiplostim as a second-line treatment before planned splenectomy in a patient with immune…

25. 11. 2022 Source: Immune Thrombocytopenia

Effectiveness of Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Clinical Practice

One of the new modalities for the treatment of ulcerative colitis (UC) is tofacitinib. Its effectiveness has already been demonstrated in clinical studies and is now being proven in real-world…

24. 11. 2022 Source: Intestinal Inflammations

Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?

A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of…

24. 11. 2022 Source: Arthritis

Current NCCN Recommendations for CLL/SLL Diagnosis –⁠ Version 1.2023

In August 2022, the latest guidelines from the National Comprehensive Cancer Network (NCCN) concerning chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were published. Here we…

23. 11. 2022 Source: Chronic Lymphocytic Leukemia

Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients

Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is…

23. 11. 2022 Source: Chronic Heart Failure and Lipidology

Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease –⁠ Prospective ELEGANCE Study

Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The…

22. 11. 2022 Source: Parkinson's Disease

First Experiences with the Combination of Levodopa/Entacapone/Carbidopa in Intestinal Gel from the Perspective of Patients with Parkinson's Disease

The work presented at the 8th Congress of the European Academy of Neurology (EAN) in Vienna in June 2022 summarizes the first experiences with the use of intestinal gel combining the active…

22. 11. 2022 Source: Parkinson's Disease

The role of the physiotherapist in hemophilia care is expanding and irreplaceable −⁠ what it entails and how it changes with treatment advances?

In the team cooperation in caring for patients with hemophilia, the physiotherapist plays a very important role, which is expanding with today's comprehensive approach to treating this condition. The…

21. 11. 2022 Source: Hemophilia with Movement

Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression

Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung…

21. 11. 2022 Source: Oncological Treatment

When the Cause of Hematomas in Anticoagulated Patients is Not Anticoagulants –⁠ Case Report

Not every bleeding during anticoagulation, especially if within the therapeutic range, can be attributed to this treatment. Particularly in older individuals and the presence of typical extensive…

18. 11. 2022 Source: Acquired Hemophilia

Rebound effect after denosumab discontinuation in a patient with lung cancer

The case study of a patient with metastatic lung cancer describes the emergence of vertebral fractures following the discontinuation of denosumab. This antiresorptive treatment was halted…

16. 11. 2022 Source: Prevention of Bone Events

1 … 39 40 41 42 43 … 115

Back Filter by speciality

Remove filters

Popular this week